Contactin-1 autoimmunity
Serologic, neurologic, and pathologic correlates
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 14, 2020
- Accepted in final form April 21, 2020
- First Published May 27, 2020.
Author Disclosures
- Divyanshu Dubey, MD,
- Josephe A. Honorat, MD*,
- Shahar Shelly, MD*,
- Christopher J. Klein, MD,
- Lars Komorowski, MD, PhD,
- John R. Mills, PhD,
- Stefanie Brakopp, PhD,
- Christian Probst, PhD,
- Vanda A. Lennon, MD PhD,
- Sean J. Pittock, MD and
- Andrew McKeon, MD
- Divyanshu Dubey, MD,
Dr. Divyanshu Dubey has attended UCB Advisory Board Meeting in Lyon, France on September 23, 2019. All compensation for consulting activities is paid directly to Mayo Clinic.
Dr. Dubey has consulted for UCB and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic.
Dr. Dubey has been a speaker at American Academy of Neurology Annual conference. All compensation for speaking activities is paid directly to Mayo Clinic.
Dr. Dubey is on the editorial board of Journal of Clinical Medicine.
Dr. Dubey has patent pending for Klech like 11 protein as a marker of neurological autoimmunity.
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Dubey has received research support from Grifols pharmaceuticals.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Josephe A. Honorat, MD*,
NONE
NONE
NONE
NONE
a patent application is pending for Septin-5-IgG as biomarker of autoimmune neurological disease.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shahar Shelly, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christopher J. Klein, MD,
I sit on the CMTA therapeutics board, CMTA is a non- profit organization.
NONE
I received honorarium for an educational talk in an Ackea sponsored symposium at the Peripheral Nerve Society meeting in June 2019.
Neuromuscular editorial board for Neurology
NONE
NONE
NONE
NONE
NONE
I attended an Polyneuropathy Advisory meeting organized by Pfizer who paid trip expense. I did not receive personal compensation.
NONE
NONE
NONE
Mayo Clinic Research Grant
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lars Komorowski, MD, PhD,
(1) I am an employee of EUROIMMUN AG, a company that develops, produces and markets diagnostic products.
NONE
NONE
NONE
NONE
NONE
Employee of EUROIMMUN AG.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John R. Mills, PhD,
NONE
NONE
NONE
NONE
Mass spectrometric measurement of monoclonal immunoglobulins for diagnosis monoclonal gammopathies
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Mass spectrometric measurement of monoclonal immunoglobulins, Technology licensing to The Binding Site company, 2017.
NONE
NONE
NONE
NONE
- Stefanie Brakopp, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Employed by Euroimmun
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Probst, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun, full-time employee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun
NONE
NONE
NONE
NONE
NONE
- Vanda A. Lennon, MD PhD,
NONE
NONE
NONE
NONE
Vanda Lennon receives royalties from RSR/Kronus for sale of aquaporin-4 autoantibody testing kits and for commercial aquaporin-4 autoantibody testing performed outside Mayo Clinic.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
MN Partnership for Biotechnology and Medical Genomics, grant # ML2017, Chapter 89, Art, section #4 (e) Sub-award # P007067701 National Institutes of Health R01 NS110949
NONE
1) RSR/Kronus for sale of aquaporin-4 autoantibody testing kits. 2) Non-Mayo sites performing "home brew" diagnostic testing for aquaporin-4 autoantibody.
Dr. Lennon has a potential financial interest in the technologies listed below: "Aquaporin-4 as an aid for cancer diagnosis".
NONE
NONE
NONE
- Sean J. Pittock, MD and
Alexion Pharmaceutical Advisory Board Medimmune/Viele Bio Advisory Board UCB pharmaceuticals Astellas
NONE
NONE
NONE
Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) - Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, and a patent Patent# 9,891,219B2 (Application#12-573942) - Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued. Dr Pittock has a patent pending for GFAP, Septin-5, Kelch11 and MAP1B autoantibodies as biomarkers of neurological autoimmunity.
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
No activity to report. I am a salaried employee of Mayo Clinic and salary is fixed specialty dependent and not impacted by test volume or laboratory income.
NONE
Dr Pittock has received research funding from Grifols, Medimmune/Viela Bio, Alexion and AEA (Autoimmune Encephalitis Associations).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew McKeon, MD
NONE
NONE
NONE
I am a member of the editorial board of Neurology: Neuroimmunology and Neuroinflammation
Patent applications pending: Septin 5, Septin 7, GFAP, PDE10A, Kelch-11 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Laboratory Medicine and Pathology, Neurology and Immunology (D.D., J.A.H., S.S., C.J.K., J.R.M., V.A.L., S.J.P., A.M.); Department of Neurology (D.D., J.A.H., S.S., C.J.K., J.R.M., V.A.L., S.J.P., A.M.), Mayo Clinic, Rochester, MN; and Euroimmun (L.K., S.B., C.P.), Lubeck, Germany.
- Correspondence
Dr. Dubey dubey.divyanshu{at}mayo.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.